Core Viewpoint - Bavarian Nordic A/S has submitted clinical data to the European Medicines Agency (EMA) to expand the use of its MVA-BN® mpox and smallpox vaccine to include children aged 2-11 years, based on positive results from a clinical trial showing comparable safety and immune responses between children and adults [1][2]. Group 1: Clinical Trial Results - The submission is based on positive topline results from a Phase 2 clinical trial (NCT06549530) involving 227 children aged 2-11 years and 224 adults, demonstrating non-inferiority of immune response and a similar safety profile between the two age groups after vaccination with two standard doses of the MVA-BN vaccine [2]. - The trial was co-funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and conducted in the Democratic Republic of Congo (DRC) and Uganda, both of which have reported cases of mpox during recent outbreaks [2]. Group 2: Regulatory and Market Implications - Following the review of these data by the EMA, the marketing authorization for MVA-BN could be expanded to include individuals aged 2 years and older later in 2026 [3]. - The submission to a WHO-recognized authority like the EMA is seen as a significant step towards protecting children globally, with the potential for other regulatory authorities to follow suit if the vaccine is approved for younger age groups [4]. Group 3: Public Health Context - The CEO of Bavarian Nordic emphasized the importance of expanding vaccine access for vulnerable populations, particularly children, who have been disproportionately affected by mpox, especially in the context of other health challenges like malnutrition and HIV [4]. - A medical expert from the University of Kinshasa noted that children aged 2 to under 12 years make up nearly one-third of the population in the DRC and are significantly impacted by complications from mpox, highlighting the need for vaccination in this age group to control outbreaks and reduce health burdens [4]. Group 4: Vaccine Information - MVA-BN, or Modified Vaccinia Ankara-Bavarian Nordic, is the only non-replicating mpox vaccine approved in the USA, Switzerland, Singapore, Mexico, Canada, and the EU/EAA, originally developed as a smallpox vaccine to ensure safety for immunocompromised individuals [5]. - The vaccine has since been approved for use in the general population aged 12 years and older who are at risk of mpox or smallpox [5]. Group 5: Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines, serving as a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness [6].